Ongoing Assessments & Recent Research.
Easy access to our work
Featured News & Insights.
Learn about our latest work.
Institute for Clinical and Economic Review Launches Program to Accelerate the Consideration of Value into Drug Development Programs
ICER will leverage its health technology assessment (HTA) expertise to encourage better evidence development in clinical trial programs.
03/25/2026Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Narcolepsy
Public comment period now open until April 7, 2026; Requests to make oral comment during public meeting also being accepted.
03/12/2026Institute for Clinical and Economic Review to Assess Treatment for Parkinson’s Disease
Report will be subject of CTAF meeting in October 2026; Draft Scoping Document open to public comment until March 27, 2026.
03/09/2026Our Origin Story.
Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 400 patient groups and patient reps
The ICER-developed Clinical trial Diversity Rating (CDR) Tool presents a framework for evaluating the demographic diversity of clinical trial populations in a consistent, transparent manner leading to an overall diversity rating. Learn more.
Current
Policy Papers.
Easy access to our latest policy papers
Launch Price and Access Report: Drug Approvals from 2022-2024
ICER conducted a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which examines launch pricing for FDA-approved treatments. This report reviewed the affordability and access of the treatments and their value to the overall health system.
Special Assessment to Inform CMS Drug Price Negotiation: Vedolizumab (Entyvio®)
ICER is developing a special report for the Centers for Medicare & Medicaid Services on a therapy for treating Crohn’s disease and ulcerative colitis. This report will be submitted to CMS as part of the 2026 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2028.
Examining Strategies to Ensure Affordable Access for Obesity Medications
ICER, in collaboration with researchers from Brown University, published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.